Financing Led by RA Capital Management with Participation from Other Existing Investors
Canaan Partners and Cenova Capital

VT3989 is the Only TEAD Autopalmitoylation Inhibitor for which Compelling Clinical Efficacy
Data Have Been Reported, Highlights Best-in-Class Profile

Funding will Support Company’s Continued Advancement of VT3989 Toward Registrational
Phase 3 Clinical Trial in Mesothelioma

 SAN MATEO, Calif., March 12, 2025 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced the closing of a $35 million Series D financing. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support the continued clinical development of the company’s first-in-class and best-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma. In conjunction with the financing, Jake Simson, Ph.D., partner at RA Capital Management, has joined the company’s board of directors.

VT3989 is a novel small molecule cancer therapeutic that targets the Hippo pathway by inhibiting palmitoylation of members of the TEAD protein family. The compound has been evaluated in more than 150 patients to date in an ongoing, open-label Phase 1 clinical study and is the first and only member of the TEAD autopalmitoylation inhibitor class for which compelling clinical efficacy data have been publicly reported. In addition to promising efficacy, VT3989 has demonstrated excellent safety in the Phase 1 trial, positioning the compound with a best-in-class profile.

Clinical findings for VT3989 have been particularly notable in patients with mesothelioma who have failed chemotherapy and immuno-oncology combination regimens, which represent the only approved therapies in this indication. These results will be presented at a major medical conference in the second half of 2025. Based on these data, Vivace is working to advance VT3989 toward a randomized registrational Phase 3 clinical trial in patients with mesothelioma and intends to discuss its plans with the United States Food and Drug Administration (FDA) later this year.

“Since participating in Vivace’s Series C round, we have had a front row seat for the tremendous progress the company has made in its efforts to address the significant unmet treatment need of patients with mesothelioma. The team’s impressive drive and continued execution made our decision to lead this Series D round an easy one,” said Dr. Simson. “Based on the clinical progress to date, we believe that VT3989 is well positioned to serve as a dramatic leap forward in the mesothelioma standard of care, offering hope to patients battling a terrible disease with limited treatment options.”

“The results of our clinical evaluation of VT3989 to date give us confidence that the appropriate next step for the program is advancement into a registrational Phase 3 trial in patients with mesothelioma. We are now laser focused on executing against this strategy, including completing our ongoing clinical study and meeting with FDA to align on next steps,” said Sofie Qiao, Ph.D., president and chief executive officer of Vivace Therapeutics. “We are grateful to RA Capital for leading this round, as well as the continued support from Canaan Partners and Cenova Capital.  This new funding will prove critical to enabling our successful development of VT3989.”

About Phase 1 study of VT3989
The Phase 1 study of VT3989 (https://clinicaltrials.gov/ct2/show/NCT04665206) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory pleural malignant mesothelioma.

About Vivace Therapeutics, Inc.
Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing a first-in-class approach to treat human carcinomas of high unmet medical needs. Based in San Francisco Bay Area, the company has raised $105 million to date. For more information, please visit www.vivacetherapeutics.com.

Contact information
Sofie Qiao, Ph.D.
President and CEO
info@vivacetherapeutics.com
650.666.2753

Tim Brons
Vida Strategic Partners (media)
646-319-8981
tbrons@vidasp.com

SOURCE Vivace Therapeutics, Inc.

Copyright © 2025 Cision US Inc.